Update on the Management of COPD

This month, E. Neil Schachter, M.D. discusses

CME credit is no longer available for this conference.

E. Neil Schachter, M.D.

Dr. Schachter reports no commercial conflict of interest.

This activity is made possible by an unrestricted educational grant from the Novartis Foundation for Gerontology.

Release Date: 11/05/1999

Upon completion of this Cyberounds^®, you should be able to:

Delineate pathophysiologic elements of COPD that determine approaches to therapy
List potential advantages/indications for the use of stereisomer specific beta agonists in COPD
Describe the role of corticosteroids in COPD.

Cystic Fibrosis -- No Longer Just a Disease of Pediatric Medicine

Emerging research suggests target-specific therapies for managing cystic fibrosis.

Authors: Arindam Singha, M.D., and Stephen E. Kirkby, M.D.

View Course

Asthma action plans are designed to be individualized and developed jointly with the patient, and may be based on symptoms or peak flow measurements.

Authors: Cathy G. Benninger, R.N., M.S., C.N.P., and Jennifer W. McCallister, M.D.

View Course

Table 1. Clinical Strategies for the Improvement of Asthma Control.

Authors: Ganesh Raghu, M.D., and Samuel G. Rayner, M.D.

View Course

Elaboration of matrix metalloproteinases (MMPs), zinc-dependent proteases, within the airways contributes to COPD.

Authors: Robert Foronjy, M.D., and Jeanine D'Armiento, M.D., Ph.D.

View Course

ALI complicates a variety of medical and surgical conditions, most commonly severe sepsis, pneumonia and massive trauma.

Authors: Chirag V. Shah, M.D., M.S., and Jason D. Christie, M.D., M.S.

View Course

This month, Victor F. Tapson, M.D., discusses

Authors: Victor F. Tapson, M.D.

View Course